Nivolumab
CAS 946414-94-4 2 FDA-DMF suppliersBiologic
Overview
Nivolumab is a human IgG4 monoclonal antibody that acts as a checkpoint inhibitor, specifically targeting the programmed death-1 (PD-1) receptor to enhance anti-tumor immunity. It is primarily used in the treatment of various cancers, including metastatic melanoma, non-small cell lung cancer, and renal cell carcinoma.
Therapeutic areas
OncologyImmunology
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.